Ubs Asset Management Americas Inc Cytom X Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $2,073 - $3,086	-480 Reduced 0.74%	64,369 $327,000
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $223,157 - $349,367	35,254 Added 119.12%	64,849 $410,000
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $130,521 - $177,984	-19,776 Reduced 40.06%	29,595 $228,000
Q3 2020 Nov 13, 2020	BUY	$6.55 - $8.83 $120,782 - $162,825	18,440 Added 59.62%	49,371 $328,000
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $25,996 - $51,430	3,513 Added 12.81%	30,931 $257,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $25,865 - $61,619	-7,165 Reduced 20.72%	27,418 $210,000
Q4 2019 Feb 14, 2020	SELL	$5.17 - $8.91 $12,775 - $22,016	-2,471 Reduced 6.67%	34,583 $287,000
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $62,656 - $104,002	8,490 Added 29.72%	37,054 $273,000
Q2 2019 Aug 15, 2019	BUY	$9.35 - $11.41 $37,156 - $45,343	3,974 Added 16.16%	28,564 $0
Q1 2019 May 14, 2019	BUY	$9.5 - $19.16 $110,105 - $222,064	11,590 Added 89.15%	24,590 $0
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $16,236 - $23,769	900 Added 7.44%	13,000 $0
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $258,698 - $359,128	12,100 New	12,100 $0

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.